A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 127-133

  Saluja, V ^a   Amorij, J P ^a,c   Kapteyn, J C ^b   de Boer, A H ^a   Frijlink, H W ^a   Hinrichs, W L J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Solvay Biologicals   (Netherlands)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Hepes buffer; Influenza vaccine; Inhalation; Phosphate buffer; Spray drying; Spray freeze drying

Indexed keywords

HEPES BUFFER; INFLUENZA VACCINES; INHALATION; PHOSPHATE BUFFERS; SPRAY FREEZE DRYING;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; DIFFUSERS (OPTICAL); IMMUNIZATION; METEOROLOGICAL INSTRUMENTS; ROTATING MACHINERY; SPRAY DRYING; VACCINES;

CURING;

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; IMMUNOGLOBULIN G; INFLUENZA VACCINE; PHOSPHATE BUFFERED SALINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRY POWDER; FEMALE; FREEZE DRYING; IMMUNIZATION; IMMUNODIFFUSION; IMMUNOGENICITY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; POWDER INHALER; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; VACCINE PRODUCTION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; DESICCATION; DOSAGE FORMS; FEMALE; FREEZE DRYING; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PARTICLE SIZE; PARTICULATE MATTER; POWDERS; VACCINES; VACCINES, SUBUNIT;

EID: 77952668173     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.025     Document Type: Article

References (42)

1. Amorij J.P., Saluja V., Petersen A.H., Hinrichs W.L., Huckriede A., Frijlink H.W. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 2007, 25(52):8707-8717.
2. Amorij J.P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 2008, 25(6):1256-1273.
3. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv. Drug. Deliv. Rev. 2006, 58(1):68-89.
4. Haigh W., Howell R.W., Meichen F.W. A comparative trial of influenza immunization by inhalation and hypojet methods. Practitioner 1973, 211(263):365-370.
5. Waldman R.H., Bond J.O., Levitt L.P., Hartwig E.C., Prather E.C., Baratta R.L., Neill J.S., Small P.A. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull. World Health Organ. 1969, 41(3):543-548.
6. Waldman R.H., Mann J.J., Small P.A. Immunization against influenza. Prev. of illness in man by aerosolized inactivated vaccine. JAMA 1969, 207(3):520-524.
7. Haigh W., Howell R.W. The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant. J. Soc. Occup. Med. 1973, 23(4):125-127.
8. Frijlink H.W., De Boer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug. Deliv. 2004, 1(1):67-86.
9. Coucke D., Schotsaert M., Libert C., Pringels E., Vervaet C., Foreman P., Saelens X., Remon J.P. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 2009, 27(8):1279-1286.
10. Garmise R.J., Staats H.F., Hickey A.J. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS Pharm.Sci.Tech. 2007, 8(4):E81.
11. S. Ohtake, R.A. Martin, L. Yee, D. Chen, D.D. Kristensen, D. Lechuga-Ballesteros, V. Truong-Le, Heat-stable measles vaccine produced by spray drying. Vaccine 28(5) 1275-1284.
12. Wong Y.L., Sampson S., Germishuizen W.A., Goonesekera S., Caponetti G., Sadoff J., Bloom B.R., Edwards D. Drying a tuberculosis vaccine without freezing. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(8):2591-2595.
13. Huang J., Garmise R.J., Crowder T.M., Mar K., Hwang C.R., Hickey A.J., Mikszta J.A., Sullivan V.J. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004, 23(6):794-801.
14. Maa Y.F., Ameri M., Shu C., Payne L.G., Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J. Pharm. Sci. 2004, 93(7):1912-1923.
15. Johnson K.A. Preparation of peptide and protein powders for inhalation. Adv. Drug Deliv. Rev. 1997, 26(1):3-15.
16. Carpenter J.F., Crowe J.H. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 1989, 28(9):3916-3922.
17. de Jonge J., Amorij J.P., Hinrichs W.L., Wilschut J., Huckriede A., Frijlink H.W. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci. 2007, 32(1):33-44.
18. Eriksson H.J., Verweij W.R., Poelstra K., Hinrichs W.L., de Jong G.J., Somsen G.W., Frijlink H.W. Investigations into the stabilisation of drugs by sugar glasses: II. delivery of an inulin-stabilised alkaline phosphatase in the intestinal lumen via the oral route. Int. J. Pharm. 2003, 257(1-2):273-281.
19. Hinrichs W.L., Prinsen M.G., Frijlink H.W. Inulin glasses for the stabilization of therapeutic proteins. Int. J. Pharm. 2001, 215(1-2):163-174.
20. Molina M.C., Armstrong T.K., Zhang Y., Patel M.M., Lentz Y.K., Anchordoquy T.J. The stability of lyophilized lipid/DNA complexes during prolonged storage. J. Pharm. Sci. 2004, 93(9):2259-2273.
21. Allison S.D., Molina M.C., Anchordoquy T.J. Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim. Biophys. Acta 2000, 1468(1-2):127-138.
22. Livingston D.P., Hincha D.K., Heyer A.G. Fructan and its relationship to abiotic stress tolerance in plants. Cell. Mol. Life Sci. 2009, 66(13):2007-2023.
23. Amorij J.P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., Frijlink H.W. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25(35):6447-6457.
24. Hinrichs W.L., Sanders N.N., De Smedt S.C., Demeester J., Frijlink H.W. Inulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes. J. Control Release 2005, 103(2):465-479.
25. Carr C.M., Chaudhry C., Kim P.S. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(26):14306-14313.
26. Remeta D.P., Krumbiegel M., Minetti C.A., Puri A., Ginsburg A., Blumenthal R. Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry 2002, 41(6):2044-2054.
27. Stegmann T., Booy F.P., Wilschut J. Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. J. Biol. Chem. 1987, 262(36):17744-17749.
28. Luykx D.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. E.ur J. Pharm. Sci. 2004, 23(1):65-75.
29. de Boer A.H., Hagedoorn P., Westerman E.M., Le Brun P.P., Heijerman H.G., Frijlink H.W. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur. J. Pharm. Sci. 2006, 28(3):171-178.
30. Kapteyn J.C., Saidi M.D., Dijkstra R., Kars C., Tjon J.C., Weverling G.J., de Vocht M.L., Kompier R., van Montfort B.A., Guichoux J.Y., Goudsmit J., Lagerwerf F.M. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 2006, 24(16):3137-3144.
31. Gomez G., Pikal M.J., Rodriguez-Hornedo N. Effect of initial buffer composition on pH changes during far-from-equilibrium freezing of sodium phosphate buffer solutions. Pharm. Res. 2001, 18(1):90-97.
32. 2O. Arch. Biochem. Biophys. 1959, 81(2):319-329.
33. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24(3):411-437.
34. Sitaula R., Bhowmick S. Moisture sorption characteristics and thermophysical properties of trehalose-PBS mixtures. Cryobiology 2006, 52(3):369-385.
35. Slade L., Levine H. Water and the class transition-dependence of the glass-transition on composition and chemical-structure - special implications for flour functionality in cookie baking. J. Food Eng. 1995, 24(4):431-509.
36. van Drooge D.J., Hinrichs W.L., Visser M.R., Frijlink H.W. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 2006, 310(1-2):220-229.
37. Maa Y.F., Nguyen P.A., Sweeney T., Shire S.J., Hsu C.C. Protein inhalation powders: spray drying vs spray freeze drying. Pharm. Res. 1999, 16(2):249-254.
38. Edwards D.A., Hanes J., Caponetti G., Hrkach J., BenJebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R. Large porous particles for pulmonary drug delivery. Science 1997, 276(5320):1868-1871.
39. Maa Y.F., Costantino H.R., Nguyen P.A., Hsu C.C. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm. Dev. Technol. 1997, 2(3):213-223.
40. de Boer A.H., Gjaltema D., Hagedoorn P., Schaller M., Witt W., Frijlink H.W. Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. Int. J. Pharm. 2002, 249(1-2):233-245.
41. Bakke H., Samdal H.H., Holst J., Oftung F., Haugen I.L., Kristoffersen A.C., Haugan A., Janakova L., Korsvold G.E., Krogh G., Andersen E.A., Djupesland P., Holand T., Rappuoli R., Haneberg B. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand. J. Immunol. 2006, 63(3):223-231.
42. Smith D.J., Bot S., Dellamary L., Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003, 21(21-22):2805-2812.